INTRODUCTION: Primary non-Hodgkin's lymphoma of the uterine cervix is a rare malignancy. The mainstay of therapy consists of irradiation alone or irradiation with either surgery or chemotherapy. CASE REPORT: We present the case of a 56-year-old woman diagnosed with a bulky, Ann Arbor stage IE, primary, diffuse, large B-cell non Hodgkin's lymphoma of the uterine cervix. We administered neoadjuvant chemotherapy according to CHOP protocol (cyclophosphamide, adriamycin, vincristine, and prednisone) followed by radical hysterectomy, bilateral salpingo-oophorectomy, and regional lymph node dissection. Clinical and pathological responses to the chemotherapy were complete. The patient is alive 5 years after the initial diagnosis. CONCLUSION: Our case emphasizes the importance of neoadjuvant chemotherapy that can provide a control of the distant microscopic metastases.
INTRODUCTION: Primary non-Hodgkin's lymphoma of the uterine cervix is a rare malignancy. The mainstay of therapy consists of irradiation alone or irradiation with either surgery or chemotherapy. CASE REPORT: We present the case of a 56-year-old woman diagnosed with a bulky, Ann Arbor stage IE, primary, diffuse, large B-cell non Hodgkin's lymphoma of the uterine cervix. We administered neoadjuvant chemotherapy according to CHOP protocol (cyclophosphamide, adriamycin, vincristine, and prednisone) followed by radical hysterectomy, bilateral salpingo-oophorectomy, and regional lymph node dissection. Clinical and pathological responses to the chemotherapy were complete. The patient is alive 5 years after the initial diagnosis. CONCLUSION: Our case emphasizes the importance of neoadjuvant chemotherapy that can provide a control of the distant microscopic metastases.
Authors: Ana María Cubo; Zandra Mileny Soto; Miguel Ángel Cruz; María José Doyague; Verónica Sancho; Aurymar Fraino; Óscar Blanco; Noemi Puig; Miguel Alcoceba; Marcos González; José María Sayagués Journal: Medicine (Baltimore) Date: 2017-05 Impact factor: 1.889